Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ordaōs-NonExomics miniPRO (3 novel targets)
- Development stage
- Preclinical
- Lead developer
- Ordaos
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
This preclinical-stage program is a collaboration between Ordaōs and NonExomics, focused on the development of miniPRO mini-proteins for the treatment of difficult-to-target rare cancers. The program targets three novel proteins identified by NonExomics from non-conventional protein-coding regions (non-exomic regions). Ordaōs utilizes its proprietary AI-driven Design Engine to generate and rank miniPRO candidates—proteins ranging from 40 to 160 amino acids—that are optimized for stability, manufacturability, and tumor microenvironment penetration.
- Other names
- miniPROOrdaōs-NonExomics mini-proteins
Beyond the preview
Go deeper on Ordaōs-NonExomics miniPRO (3 novel targets).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ordaōs-NonExomics miniPRO (3 novel targets).